Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:1985
|
| gptkbp:available_on |
generic version
|
| gptkbp:clinical_trial |
studies on endometriosis
studies on precocious puberty studies on prostate cancer |
| gptkbp:contraindication |
pregnancy
breastfeeding |
| gptkbp:dosage_form |
injectable solution
|
| gptkbp:duration |
varies by condition
|
| gptkbp:effective_date |
FDA approved
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lupron Injection
|
| gptkbp:ingredients |
gptkb:leuprolide_acetate
|
| gptkbp:interacts_with |
may interact with anticoagulants
may interact with other hormone therapies |
| gptkbp:is_involved_in |
adult men
women with endometriosis children with precocious puberty |
| gptkbp:is_monitored_by |
bone density
hormone levels |
| gptkbp:manufacturer |
gptkb:Abb_Vie
|
| gptkbp:mechanism_of_action |
gptkb:Hirogen
|
| gptkbp:patient_education |
inform about side effects
advise on injection technique discuss treatment goals |
| gptkbp:price |
varies by location
may be covered by insurance |
| gptkbp:provides_guidance_on |
ASCO guidelines
NCCN guidelines |
| gptkbp:research_focus |
long-term effects
quality of life assessments comparative effectiveness |
| gptkbp:route_of_administration |
intramuscular injection
subcutaneous injection |
| gptkbp:service_frequency |
monthly
every six months every three months |
| gptkbp:side_effect |
fatigue
nausea cardiovascular issues thromboembolic events weight gain anaphylaxis osteoporosis mood changes hot flashes |
| gptkbp:storage |
refrigerated
|
| gptkbp:trade |
gptkb:Lupron
|
| gptkbp:used_for |
treating endometriosis
treating precocious puberty treating prostate cancer |
| gptkbp:bfsParent |
gptkb:Lupron
|
| gptkbp:bfsLayer |
6
|